In any case, the researchers agree that these basic research findings provide an early warning to
pharmaceutical drug developers.
Not exact matches
• Biohaven
Pharmaceuticals, a New Haven, Conn. - based neurological disease
drug developer, set terms for its IPO.
• NovaQuest Capital Management agreed to acquire
drug developer Viamet
Pharmaceuticals, a Durham, N.C. - based
developer of novel antifungal agents.
According to the press release, attendees will include representatives from «the US Food and
Drug Administration (FDA), innovation leaders from the world's largest
pharmaceutical organizations, and leading blockchain
developers.»
Two private equity firms will pay $ 1.23 billion for Australian
drug developer and marketer iNova
Pharmaceuticals, in the latest sign that private equity buyers are cashed up and willing to write big cheques.
On November 21st, a relatively small biotech company named Gilead Sciences (GILD) made headline news in the
pharmaceutical investment community when it acquired a little - known hepatitis C
drug developer named Pharmasset Inc. (VRUS), for $ 10.8 billion, in an all - cash deal.
No. 1: Medical marijuana laws are passed, but GW
Pharmaceuticals shares will continue to drop Admittedly, this is a new spin on my 2015 prediction that shares in marijuana
drug developer GW
Pharmaceuticals plc (NASDAQ: GWPH) would fall because of trial failures.
In a report, the commission argues that «[g] lobal governments should unite to offer multibillion - dollar incentives for
drug developers, and
pharmaceutical companies should pool their billions in support of early - stage research,» as Kelly Servick wrote Thursday at ScienceInsider.
Biotech
drug developer Myriad
Pharmaceuticals (MYRX) joins the list in second place, as the company has net cash of $ 169 million versus market value of $ 135 million.